SDF-1α decreased apoptosis in neonate cardiomyocytes. by Ielham Hadad (382805)

L-2286 treatment decreased the deposition of interstitial collagen. by Laszlo Deres (596720)

IRE1 depletion decreases heterochromatin, DNA and H3K9me3 methylation, and UHRF1. by Iratxe Zuazo-Gaztelu (21071939)

MEK inhibition decreases mTOR activity in T cells. by Marie Le Borgne (337225)

MMR mutants show decreased mating-type silencing. by Qian Liu (135614)

“…<i>sir1Δ</i> mutant was used as a positive control. <b>(D)</b> Cells of indicated strains were 10-fold serially diluted and then spotted onto SC (left), SD-Ura (middle) and SC+FOA(right) agar plates, the <i>sir1Δ</i> mutant served as a positive control. …”

Pyrimidine nucleotides are decreased in hypoxia, while precursors accumulate. by Emily B. Cohen (9106088)

Epidermal GATA3 expression is decreased in psoriatic lesions. by Emőke Rácz (220871)

GSK343 decreased neuroblastoma viability, proliferation, and motility. by Laura V. Bownes (10276762)

“…<p>(A) SK-N-AS, SK-N-BE(2), SH-EP and WAC(2) cells (1.5 × 10³ cells) were treated with increasing concentrations of GSK343 (0, 5, 15, 25 μM) for 24 hours and viability was measured using alamarBlue^® assay. …”

<i>ism1</i> knockdown decreases erythrocytes. by Arturo Berrun (5216003)

Bortezomib decreases osteoclasts and improves fracture repair in mice. by Hengwei Zhang (2397610)

RGDfV increases ASM mRNA, ASM activity and ceramide levels and decreases sphingomyelins. by Xiuhai Ren (312555)

Forty-two receptors arranged in order of decreasing interaction with the full set of thirty-five drugs. by Thomas S. Ray (253767)

“…The black vertical bars represent a 100-fold drop in affinity relative to the receptor with the highest affinity at each drug. …”

Decrease in CD15⁺ and CD133⁺ expression in Daoy cells under hypoxia condition, upon miR-34a overexpression. by Pasqualino de Antonellis (206257)

VRK1 overexpression is seen in human breast cancer and is associated with decreased relapse-free survival. by Aye M. Mon (5714912)

“…Data for cancer subtypes are shown in boxes numbered 1–11: 1: benign breast neoplasm (rank 6459, 1.4 fold-change, NS), 2: breast carcinoma (rank 833, 1.5 fold-change, p = 3.83x10^-5), 3: breast phyllodes tumor (rank 512, 1.2 fold-change, p = 0.002), 4: ductal breast carcinoma in situ (rank 1969, 1.5 fold-change, p = 0.002), 5: invasive breast carcinoma (rank 1060, 1.6 fold-change, p = 1.28x10^-5), 6: invasive ductal and invasive lobular breast carcinoma (rank 941, 1.5 fold-change, p = 6.76x10^-22), 7: invasive ductal breast carcinoma (rank 613, 1.5-fold change, p = 2.71x10^-71), 8: invasive lobular breast carcinoma (rank 947, 1.3 fold-change, p = 3.64x10^-28), 9: medullary breast carcinoma (rank 400, 1.8 fold-change, p = 3.25x10^-12), 10: mucinous breast carcinoma (rank 1932, 1.4 fold-change, p = 7.41x10^-10) and 11: tubular breast carcinoma (rank 1253, 1.4 fold-change, p = 1.24x10^-17). …”

Effect of DFATs implantation on the inhibition of atrophy in the atrophic vocal fold muscle. by Ikuo Mikoshiba (9312007)

Subjects:

Equilibrium points and their corresponding eigenvalues of Eq (5). by Xinghua Fan (7344632)

Analysis of sphingosine levels from BAL. by Henning Carstens (13132801)

Histological studies of lungs stained with Cy3-coupled anti-sphingosine antibodies. by Henning Carstens (13132801)

Histological studies of lungs stained with Cy3-coupled anti-ceramide antibodies. by Henning Carstens (13132801)

Fig 7 - by Henning Carstens (13132801)